2. Signaling Pathways
  3. Immunology/Inflammation
  4. LILRB
  5. LILRB2 Isoform
  6. LILRB2 Inhibitor

LILRB2 Inhibitor

LILRB2 Inhibitors (3):

Cat. No. Product Name Effect Purity
  • HY-P990061
    Polzastobart
    		Inhibitor
    Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor.
  • HY-P992388
    IO-108
    		Inhibitor
    IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors.
  • HY-P991306
    ATG-032
    		Inhibitor
    ATG-032 is a human monoclonal antibody (mAb) targeting LILRB2/ILT4. ATG-032 can be used in haematological malignancies research.